Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the breast;

- Female subjects with non-metastatic disease who are estrogen receptor (ER) and/or
progesterone receptor (PR) positive, and who have completed their treatment pathway;

- Subjects who are currently on, or will initiate an approved non-steroidal aromatase
inhibitor therapy (eg, anastrazole) in the adjuvant setting;

- Postmenopausal woman, defined as a woman fulfilling any one of the following
criteria:

- Having undergone a bilateral oophorectomy;

- Age ≥ 60 years;

- Aged < 60 years meeting the following requirements:

- FSH and estradiol in the postmenopausal range;

- A negative pregnancy test within 7 days prior to randomization. Subjects who have
undergone a hysterectomy do not require a pregnancy test.

- More criteria may apply.

Exclusion Criteria:

- Aromatase inhibitor therapy for more than 24 months;

- Prior or concurrent treatment with Selective Estrogen Receptor Modulators (eg,
tamoxifen);

- Evidence of metastatic disease;

- Current or prior IV bisphosphonate administration;

- Oral bisphosphonate treatment greater than or equal to 3 years continuously OR
greater than 3 months but less than 3 years unless there was a washout period of at
least 1 year prior to randomization OR any use during the 3-month period prior to
randomization;

- Prior administration of denosumab;

- Known liver or renal deficiency;

- Recurrence of the primary malignancy (eg, during the allowed interval of pretreatment
with aromatase inhibitor);

- Diagnosis of any second non-breast malignancy within the last 5 years, except for
adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma
of the cervix uteri;

- Any kind of disorder that compromises the ability to give written informed consent
and/or comply with study procedures;

- More criteria may apply.